GU Cancers 2021 | Favorable traits in metastatic RCC

Andrew Schmidt, MD, B.Pharm, Dana-Farber Cancer Institute, Boston, MA, discusses the findings of a study analyzing data from 1638 patients with metastatic renal cell carcinoma (RCC) that had favorable-risk disease according to the International Metastatic RCC Database Consortium (IMDC) criteria. The study aimed to identify a subset of patients who may be suitable for less intensive therapy. Primary diagnosis to systemic therapy, Karnofsky performance status and the presence of brain, liver or bone metastases were found to be significant predictors of overall survival (OS). This interview took place during the 2021 Genitourinary Cancers Symposium.